Abstract
Introduction: Depression is a leading cause of disability worldwide, with significant treatment gaps in low-resource settings like Nepal. Escitalopram, a selective serotonin reuptake inhibitor (SSRI), and duloxetine, a serotonin-norepi
References
Herrman H, Kieling C, McGorry P, Horton R, Sargent J, Patel V. Reducing the global burden of depression: a Lancet–World Psychiatric Association Commission. The Lancet. 2019;393(10189):e42–3. [PubMed | Full Text | DOI]
Patel V, Chisholm D, Parikh R, Charlson FJ, Degenhardt L, Dua T, et al. Addressing the burden of mental, neurological, and substance use disorders: key messages from Disease Control Priorities. The Lancet. 2016;387(10028):1672–85. [PubMed | Full Text | DOI]
Dhimal M, Dahal S, Adhikari K, Koirala P, Bista B, Luitel N, et al. A Nationwide Prevalence of Common Mental Disorders and Suicidality in Nepal: Evidence from National Mental Health Survey, 2019-2020. J Nepal Health Res Counc. 2022;19(4):740–7. [PubMed | Full Text | DOI]
Edinoff AN, Akuly HA, Hanna TA, Ochoa CO, Patti SJ, Ghaffar YA, et al. Selective serotonin reuptake inhibitors and adverse effects: a narrative review. Neurol Int. 2021;13(3):387–401. [PubMed | Full Text | DOI]
Khan A, Bose A, Alexopoulos GS, Gommoll C, Li D, Gandhi C. Double-Blind Comparison of Escitalopram and Duloxetine in the Acute Treatment of Major Depressive Disorder. Clin Drug Investig. 2007;27(7):481–92. [PubMed | Full Text | DOI]
Montgomery SA, ?sberg M. A New Depression Scale Designed to be Sensitive to Change. Br J Psychiatry. 1979;134(4):382–9. [PubMed | Full Text | DOI]
Nierenberg AA, Greist JH, Mallinckrodt CH, Prakash A, Sambunaris A, Tollefson GD, et al. Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study. Curr Med Res Opin. 2007;23(2):401–16. [PubMed | Full Text | DOI]
Wade A, Gembert K, Florea I. A comparative study of the efficacy of acute and continuation treatment with escitalopram versus duloxetine in patients with major depressive disorder. Curr Med Res Opin. 2007;23(7):1605–14. [PubMed | Full Text | DOI]
Trivedi M, Kholi A, Verma V, Dixit R. Comparative study of safety and efficacy of duloxetine versus escitalopram: A randomized control trial. Int J Pharm Psychopharmacol Res. 2012;2(3):216–21. [Google Scholar]
Organization WH. Mental Health Gap Action Programme (mhGAP) guideline for mental, neurological and substance use disorders. World Health Organization; 2023. [Full Text]
Kazdin AE, Harris MG, Hwang I, Sampson NA, Stein DJ, Viana MC, et al. Patterns, predictors, and patientreported reasons for antidepressant discontinuation in the WHO World Mental Health Surveys. Psychol Med. 2024;54(1):67–78. [PubMed | Full Text | DOI]
Shelton RC. Serotonin and norepinephrine reuptake inhibitors. In: Antidepressants: From Biogenic Amines to New Mechanisms of Action. Springer; 2019. p. 145–80. DOI 13. Balda?ara L. Duloxetine: an update. Res Soc Dev. 2024;13(3):e7313345331–e7313345331. [Full Text | DOI]
Yin J, Song X, Wang C, Lin X, Miao M. Escitalopram versus other antidepressive agents for major depressive disorder: a systematic review and metaanalysis. BMC Psychiatry. 2023;23(1):876. [PubMed | Full Text | DOI]
Wang SM, Han C, Bahk WM, Lee SJ, Patkar AA, Masand PS, et al. Addressing the side effects of contemporary antidepressant drugs: a comprehensive review. Chonnam Med J. 2018;54(2):101–12. [PubMed | Full Text | DOI]
Rodrigues-Amorim D, Olivares JM, Spuch C, RiveraBaltanás T. A systematic review of efficacy, safety, and tolerability of duloxetine. Front Psychiatry. 2020;11:554899. [PubMed | Full Text | DOI]
Sobieraj DM, Martinez BK, Hernandez AV, Coleman CI, Ross JS, Berg KM, et al. Adverse effects of pharmacologic treatments of major depression in older adults. J Am Geriatr Soc. 2019;67(8):1571–81. [PubMed | Full Text | DOI]
Merel SE, Paauw DS. Common drug side effects and drug-drug interactions in elderly adults in primary care. J Am Geriatr Soc. 2017;65(7):1578–85. [PubMed | Full Text | DOI]
